Yungan Tao

Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial

Jean Bourhis, Christian Sire, P. Gräff et al. · The Lancet Oncology · 2012 · 382 citations

Medicine, Oncology, Radiation Oncology +11

International guideline for the delineation of the clinical target volumes (CTV) for nasopharyngeal carcinoma

Anne W.M. Lee, Wai Tong Ng, Sharon Shuxian Poh et al. · Radiotherapy and Oncology · 2017 · 376 citations · Full text

Medicine, Radiation Oncology, Radiology +14

Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial

Jean‐Pascal Machiels, Yungan Tao, Lisa Licitra et al. · The Lancet Oncology · 2024 · 210 citations · Full text

Medicine, Oncology, Pharmacology +16

Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial

Yungan Tao, J. Biau, X.S. Sun et al. · Annals of Oncology · 2022 · 177 citations · Full text

Medicine, Oncology, Radiation Oncology +13

A randomized trial of induction docetaxel–cisplatin–5FU followed by concomitant cisplatin-RT versus concomitant cisplatin-RT in nasopharyngeal carcinoma (GORTEC 2006-02)

M. Frikha, A. Aupérin, Yungan Tao et al. · Annals of Oncology · 2017 · 172 citations

Medicine, Oncology, Radiation Oncology +15